14 - 21 April 2017
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts
Genes and MS risk
Tecfidera and NEDA
Further analysis of trial results found that more people taking Tecfidera (dimethyl fumarate) achieved no evidence of disease activity (NEDA) - defined as no relapses, no increase in disability over 12 weeks as measured by EDSS, and no new lesions. About one in four of the people on Tecfidera showed no activity compared to about one in eight in a placebo group
Source: Neurology Advisor
MS Trust link: MS Decisions - a guide to the disease modifying drugs